Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.
In human, catechol-O-methyltransferase (COMT: E.C. 2.1.1.6) is responsible for metabolism of catechol neurotransmitter and xenobiotics. The main clinical interest in COMT results from the possibility of using COMT inhibitors as adjuncts in the therapy of Parkinson's disease (PD) with l-DOPA. COMT is therefore a target for inhibitor development aiming at PD treatment and has been submitted to extensive structure-based drug design. Recently reported inhibitors have nitrocatechol structure that may inhibit oxidative phosphorylation and uncouple mitochondrial energy production. This work reports the first crystallographic study of Rat COMT complexed with non-nitrocatechol inhibitor. Analysis of the structural differences among the previously reported inhibitor complexes, coumarine-based inhibitor (4-phenyl-7, 8-dihydroxycoumarine: 4PCM) bound structure provides the explanation for inhibitor binding and can be used for future inhibitor design.
Tsuji
Eiichi
E
Molecular Design Research, R&D Kissei Pharmaceutical Co., Ltd. 4365-1 Kashiwabara, Hotaka, Azumino-city, Nagano 399-8304, Japan.
Okazaki
Kosuke
K
Takeda
Kei
K
D000818:Animals; D000978:Antiparkinson Agents / Q000737:chemistry* / Q000494:pharmacology; D001665:Binding Sites; D002394:Catechol O-Methyltransferase / Q000737:chemistry*; D065098:Catechol O-Methyltransferase Inhibitors; D003374:Coumarins / Q000737:chemistry* / Q000494:pharmacology; D018360:Crystallography, X-Ray; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D010300:Parkinson Disease / Q000201:enzymology*; D011487:Protein Conformation; D051381:Rats; D014468:Umbelliferones / Q000737:chemistry* / Q000494:pharmacology
C534482:4-phenyl-7,8-dihydroxycoumarin; D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D003374:Coumarins; D004791:Enzyme Inhibitors; D014468:Umbelliferones; D002394:Catechol O-Methyltransferase